FDA to Evaluate Pediatric Cough Medicines Containing Opioids
A meeting of the Pediatric Advisory Committee will advise on the use of prescription opioid medications containing hydrocodone or codeine in children’s cough medicine.
On August 21, 2017, FDA Commissioner Scott Gottlieb announced that FDA will be evaluating the “complex issue” of the use by children of prescription opioid products containing hydrocodone or codeine. A meeting of the Pediatric Advisory Committee will look at the benefits and risks of the pediatric use of cough medicines containing opioids. The agency will also use information gained during a roundtable of professional groups held in April 2017.
“It is vital we understand the potential complications that can occur when using opioid-containing medications in children, even according to labeled instructions. This is an area that the agency is continuing to evaluate,” Gottlieb said in a statement.
In April 2017, the agency announced changes to the labeling of opioid medications to protect children from the risks associated with these medications. The changes included adding alerts that codeine should not be used in children under 12 years of age.
Source: FDA
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
